Navigation Links
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Date:11/10/2008

this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

To date, over 1,700 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in lower doses that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocel
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
6. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
7. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
8. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
9. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
10. Lippincott Williams & Wilkins Selected as Publisher of the Journal of Neuroscience Nursing
11. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Sunrise, FL (PRWEB) March 05, 2015 ... appear at this week’s Arnold Sports Festival and ... March 5-8. Metabolic Nutrition will host a display ... its all-new pre-workout E.S.P. and its highly-popular, class-leading fat ... free shaker cups, unique recipes that utilize its top-of-the-line ...
(Date:3/5/2015)... Think it’s tough to get kids to ... them to brush their teeth. That’s a finding from a ... Delta Dental(1) in conjunction with National Parenting Month in March. ... kids to brush their teeth is one of the most ... higher than getting children to eat vegetables regularly (42 percent) ...
(Date:3/5/2015)... DE (PRWEB) March 05, 2015 The ... false weight loss promises is alarming, with more and ... products without an actual prescription, making it easy for ... that simply take their money and endanger their health. ... questions before purchasing prescription online diet pills: , 1.    Where ...
(Date:3/5/2015)... The MTC 5-day Fundamental Implantology Course ... from a variety of dental disciplines, to offer implant ... "From the onset we wanted this course to be ... to the excellence of the lecturers and the sheer ... more than satisfied our aims." , Unlike large-scale ...
(Date:3/5/2015)... Plains, NY (PRWEB) March 05, 2015 Hope ... New York Sporting Clay Shoot to be held at Beretta ... May 15, 2015. All proceeds from the event will benefit ... a sense of self, restoring the family unit, and restoring ... The event will honor our nation’s heroes through a day ...
Breaking Medicine News(10 mins):Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2Health News:Hope For The Warriors Announces New York Clay Shoot to Benefit Military Families 2
... by the National Human Genome Research Institute (NHGRI), has ... shows promise in laboratory studies for treating a fatal ... ,These drugs belong to a class of farnesyltransferase inhibitors ... myeloid leukemia, neurofibromatosis and other conditions. It could also ...
... Brisk walks or running may reduce the risk of ovarian cancer, ... may reduce the risk of some other forms of cancer. ... a 70 % reduction in the risk of development of ovarian ... colon cancer was also less frequent among those who exercised. ...
... behaviors, like over speeding, more in company of same ... sex. ,The study was published on-line edition of ... ,The findings indicate that teen risky driving increases in ... But more important, the finding should remind teens-and the ...
... from University of Pennsylvania had identified a brain chemical ... abuse. The chemical called orexin is also involved in ... ,Research showed that the activation of ... that controls many vital functions such as eating, body ...
... couples trying to conceive that is, one in every six ... a problem with conception. ,With this being the clinical ... is increasing day by day. // In spite of ... to physical, mental and psychological trauma. Anxiety of patients regarding ...
... by AUT Professor of Nutrition Elaine Rush states that ... sugar as well as caffeine contributes to obesity. // ... containing sugar, added caffeine and guarana (which also contains ... more rapidly than lemonade. "These results could have huge ...
Cached Medicine News:Health News:Brain Chemical Identified For Drug Dependent Behavior 2Health News:Will anxiety regarding fertility treatment affect the chances of conception? 2Health News:Obesity Can Be Caused By Consumption Of Energy Drinks 2
(Date:3/5/2015)... March 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") ... it has acquired the approved abbreviated new drug ... 100mg and 150mg, previously marketed by Teva Pharmaceuticals.  ... this product was approximately $39 million in 2014. ... President and CEO of ANI Pharmaceuticals, stated, "This ...
(Date:3/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/gl7m98/japan_pharma ) has ... 2015: Year to Watch out for Authorized Generics (AGs), ... offering. The new pricing system adopted ... (Annexure 1) is a game changer initiative. It pains ... The most of the companies are revalidating their domestic ...
(Date:3/5/2015)... , March 5, 2015 ... the new generation of OASIS *    at ... enhanced processing power will set a benchmark for patient-centric ... obstacles and prevent delays whilst optimizing workflow management and ... patient comfort and safety for imaging in Neurology, Orthopaedics, ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 2Hitachi Medical Systems Europe Launches the New Generation of OASIS*- The World's Most Powerful Open High-Field 1.2T MRI - A New Level in Patient-Centric Care 3
... , BROOKFIELD, Wis. , ... human resources and recruitment outsourcing company, today announced the addition ... Kaiser Permanente Mid-Atlantic States Region, to its Healthcare Advisory Board. ... during this time of monumental change in the healthcare industry. ...
... , MELVILLE, N.Y. , Jan. 25 ... HSIC ), the largest distributor of health care products and services ... of Bradley T. Sheares , Ph.D. to the Company,s Board ... Sheares brings a wealth of health care experience to the Henry ...
Cached Medicine Technology:Pinstripe Welcomes Carrie Harris-Muller To Board 2Pinstripe Welcomes Carrie Harris-Muller To Board 3Pinstripe Welcomes Carrie Harris-Muller To Board 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 2Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 3Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 4Henry Schein Elects Dr. Bradley T. Sheares to Board of Directors 5
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
For the quantitative in vitro determination of Triglycerides in serum and plasma....
CK-MB Control...
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
Medicine Products: